Showing results (431-440 of 466) with videos related to

Sort By:
Pageof 47
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Diagnostics (Basel, Switzerland)|February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research DatabaseGemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Lancet. Rheumatology|May 17, 2025
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort studyAnna-Maria Hoffmann-Vold, Liubov Petelytska, Håvard Fretheim, et al.
Annals of the Rheumatic Diseases|October 11, 2024
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Lancet. Respiratory Medicine|June 5, 2026
Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statementJoshua J Solomon, Philippe Dieudé, Scott M Matson, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2020
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension TrialsKristin K Jørgensen, Guro L Goll, Joe Sexton, et al.
Research Square|February 12, 2026
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisJustin Oldham, Philip Molyneaux, Manoj Maddali, et al.
The European Respiratory Journal|September 4, 2025
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)Katerina M Antoniou, Oliver Distler, Ana-Maria Gheorghiu, et al.
Pageof 47